Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

BA-BE Studies: SOP for Partial and Failed Analytical Runs – V 2.0

Posted on By

BA-BE Studies: SOP for Partial and Failed Analytical Runs – V 2.0

Standard Operating Procedure for Handling Partial and Failed Analytical Runs in BA/BE Studies

Department BA-BE Studies
SOP No. SOP/BA-BE/165/2025
Supersedes SOP/BA-BE/165/2022
Page No. Page 1 of 10
Issue Date 17/04/2025
Effective Date 20/04/2025
Review Date 17/04/2026

1. Purpose

To establish a uniform procedure for identifying, documenting, and managing partial and failed analytical runs during LC-MS/MS bioanalysis in BA/BE studies, ensuring data quality and regulatory adherence.

2. Scope

This SOP applies to all bioanalytical scientists and QA reviewers involved in handling, documenting, and approving LC-MS/MS runs associated with BA/BE plasma sample analysis.

3. Responsibilities

  • Analyst: Monitors
run integrity, identifies failures, documents observations, and proposes corrective actions.
  • Lab Supervisor: Reviews reasons for failure, approves reanalysis plans, and ensures proper documentation.
  • QA: Audits failed run records and ensures CAPA implementation where required.
  • 4. Accountability

    The Bioanalytical Laboratory Head is accountable for ensuring failed or partial runs are handled per regulatory expectations and are appropriately justified and recorded.

    5. Procedure

    5.1 Definitions

    • Partial Run: A run in which only part of the sequence was completed or part of the data is unusable due to instrument, sample, or operational issues.
    • Failed Run: A run where the calibration curve fails to meet acceptance criteria, invalidating the entire batch.

    5.2 Identification of a Partial or Failed Run

    1. Monitor every run for:
      • Calibration curve linearity and back-calculated concentrations.
      • System Suitability Test (SST) results.
      • Internal standard response consistency.
      • Chromatographic anomalies (e.g., split peaks, baseline drift).
    2. If any of the above fail, classify the run as partial or failed and halt further injections.

    5.3 Documentation

    1. Document failed/partial run in Annexure-1: Run Failure Record.
    2. Include chromatograms, SST, calibration data, and reasons for run failure.
    3. Flag all data as “Do Not Use” in raw data folder and label with a red tag.

    5.4 Root Cause Investigation

    1. Investigate the issue under supervision:
      • Instrument malfunction: Check logs, gas supply, pressure, pump performance.
      • Sample preparation error: Re-extract QC and study samples.
      • Software/data acquisition error: Report and validate sequence file settings.
    2. Record the investigation in Annexure-2: Run Investigation Log.

    5.5 Approval for Reanalysis

    1. Submit justification for reanalysis to Lab Supervisor and QA.
    2. Approval to repeat analysis must be documented and attached to raw data package.

    5.6 Reprocessing vs Reanalysis

    1. Reprocessing: Acceptable if raw data (chromatograms) is intact and original integration was erroneous.
    2. Reanalysis: Required if:
      • Sample vials were not injected.
      • System issues impacted ionization.
      • Inappropriate results due to matrix effects, degradation, etc.
    3. All reanalysis activities must be documented in Annexure-3: Reanalysis Approval Form.

    5.7 Data Archival and Final Reporting

    1. Clearly segregate valid and invalid runs in the final report and assign separate identifiers (e.g., RUN-01F for failed).
    2. Attach failure justification, corrected data, and impact analysis in the final bioanalytical report.

    6. Abbreviations

    • BA/BE: Bioavailability/Bioequivalence
    • SST: System Suitability Test
    • QC: Quality Control
    • CAPA: Corrective and Preventive Action
    • QA: Quality Assurance

    7. Documents

    1. Run Failure Record – Annexure-1
    2. Run Investigation Log – Annexure-2
    3. Reanalysis Approval Form – Annexure-3

    8. References

    • ICH M10: Bioanalytical Method Validation
    • FDA Bioanalytical Method Validation Guidance
    • Internal Quality System Manual

    9. SOP Version

    Version: 2.0

    10. Approval Section

    Prepared By Checked By Approved By
    Signature
    Date
    Name
    Designation
    Department

    11. Annexures

    Annexure-1: Run Failure Record

    Run ID Date Reason for Failure Initiated By Reviewed By
    RUN-102 15/04/2025 Curve R² < 0.98 Sunita Reddy QA Officer

    Annexure-2: Run Investigation Log

    Run ID Observation Investigation Summary Corrective Action
    RUN-102 Low peak area for all QCs Column pressure dropped Column replaced

    Annexure-3: Reanalysis Approval Form

    Date Sample IDs for Reanalysis Reason Approved By
    16/04/2025 BE001-TP3, BE001-TP5 Pump failure during injection Lab Supervisor

    Revision History:

    Revision Date Revision No. Details Reason Approved By
    01/01/2022 1.0 Initial issue New SOP QA Head
    17/04/2025 2.0 Added definitions and reprocessing policy Regulatory update QA Head
    See also  BA-BE Studies: SOP for Dose Selection Criteria for BA/BE Studies - V 2.0
    BA-BE Studies V 2.0 Tags:Absolute bioavailability, AUC (area under the curve), Bioavailability, Bioequivalence, Bioequivalence criteria, CDSCO bioequivalence norms, Clinical trial registration, Cmax (maximum concentration), Confidence interval %, Crossover study design, EMA bioequivalence requirements, Ethics committee approval, FDA bioequivalence guidelines, Generic drug approval, Good Clinical Practice (GCP), Good Laboratory Practice (GLP), Half-life (t½), ICH E(R) compliance, In vitro dissolution, In vivo studies, Informed consent process, Pharmacodynamics, Pharmacokinetics, Randomized controlled trial, Regulatory submission process, Relative bioavailability, Sample size calculation, Therapeutic equivalence, Tmax (time to maximum concentration), Washout period

    Post navigation

    Previous Post: Elixir Department: SOP for Transfer of Bulk Elixir to Storage Tank – V 2.0
    Next Post: Biosimilars: SOP for Centrifugation of Harvested Broth in Bioreactor Operations – V 2.0

    Standard Operating Procedures V 1.0

    • Aerosols
    • Analytical Method Development
    • Bioequivalence Bioavailability Study
    • Capsule Formulation
    • Clinical Studies
    • Creams
    • Data Integrity
    • Dental Dosage Forms
    • Drug Discovery
    • Environment, Health and Safety
    • Formulation Development
    • Gels
    • Good Distribution Practice
    • Good Warehousing Practices
    • In-Process Control
    • Injectables
    • Liquid Orals
    • Liposome and Emulsion Formulations
    • Lotions
    • Lyophilized Products
    • Maintenance Dept.
    • Medical Devices
    • Metered-Dose Inhaler
    • Microbiology Testing
    • Nanoparticle Formulation
    • Nasal Spray Formulations
    • Nebulizers
    • Ocular (Eye) Dosage Forms
    • Ointments
    • Otic (Ear) Dosage Forms
    • Pharmacovigilance
    • Powder & Granules
    • Purchase Departments
    • Quality Assurance
    • Quality Control
    • Raw Material Stores
    • Regulatory Affairs
    • Tablet Manufacturing
    • Rectal Dosage Forms
    • Transdermal Patches
    • Vaginal Dosage Forms
    • Validations and Qualifications

    Read SOPs in your Language:

     - 
    Bengali
     - 
    bn
    English
     - 
    en
    Gujarati
     - 
    gu
    Hindi
     - 
    hi
    Malayalam
     - 
    ml
    Marathi
     - 
    mr
    Punjabi
     - 
    pa
    Tamil
     - 
    ta
    Telugu
     - 
    te

    NEW! Revised SOPs – V 2.0

    • Aerosols V 2.0
    • Analytical Method Development V 2.0
    • API Manufacturing V 2.0
    • BA-BE Studies V 2.0
    • Biosimilars V 2.0
    • Capsules V 2.0
    • Creams V 2.0
    • Elixers V 2.0
    • Gels V 2.0
    • Injectables V 2.0
    • Ointments V 2.0
    • Raw Material Warehouse V 2.0
    • Tablet Manufacturing V2.0

    New Publication: A must for All.

    Copyright © 2026 SOP Guide for Pharma.

    Powered by PressBook WordPress theme

    Go to mobile version